Double-blind clonazepam vs placebo in panic disorder treatment
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the effectiveness of clonazepam, in a fixed dose (2 mg/day), compared with placebo in the treatment of panic disorder patients. METHOD: 24 panic disorder patients with agoraphobia were randomly selected. The diagnosis was obtained using the structured clinical interview for DSM-IV . All twenty-four subjects were randomly assigned to either treatment with clonazepam (2 mg/day) or placebo, during 6 weeks. Efficacy assessments included: change from baseline in the number of panic attacks; CGI scores for panic disorder; Hamilton rating scale for anxiety; and panic associated symptoms scale. RESULTS: At the therapeutic endpoint, only one of 9 placebo patients (11.1%) were free of panic attacks, compared with 8 of 13 (61.5%) clonazepam patients (Fisher exact test; p=0,031). CONCLUSION: the results provide evidence for the efficacy of clonazepam in panic disorder patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ballenger, J. C. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800290027004 · Cited by 564
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Mitte, K. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.05.003 · Cited by 396
Risks and benefits of medications for panic disorder: A comparison of SSRIs and benzodiazepines
Quagliato, L. A., Freire, R. C., & Nardi, A. E. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1429403 · Cited by 62
“[50] treated 24 PD patients with clonazepam 2 mg/day or placebo.”
MethodNardi, A. E., Freire, R. C., Mochcovitch, M. D., Amrein, R., Levitan, M. N., King, A. L., Valença, A. M., Veras, A. B., Paes, F., Sardinha, A., et al. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823fe4bd · Cited by 56
“In this study, drowsiness and memory/concentration problems were the most common AEs with clonazepam, consistent with other studies.(14,16) The amnestic effects of benzodiazepines have been well documented.”
ResultSelf-citationBenzodiazepines and anxiety disorders: a review for the practicing physician
Kaplan, E. M., & DuPont, R. L. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x48401 · Cited by 55
Metadata
- Authors
- VALENÇA, A. M., NARDI, A. E., NASCIMENTO, I., MEZZASALMA, M. A., LOPES, F. L., & ZIN, W.
- Venue
- Arquivos de Neuro-Psiquiatria
- Publisher
- FapUNIFESP (SciELO)
- Published
- 2000-12
- Volume
- 58
- Issue
- 4
- Pages
- 1025-1029
- ISSN
- 0004-282X (ISSN-L)
- OpenAlex
- W2029052259
- Cited by
- 38
- References
- 1
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Double-blind clonazepam vs placebo in panic disorder treatment. https://app.cochat.ai/papers/10.1590/s0004-282x2000000600008
- The paper
- VALENÇA, A. M., NARDI, A. E., NASCIMENTO, I., MEZZASALMA, M. A., LOPES, F. L., & ZIN, W. (2000). Double-blind clonazepam vs placebo in panic disorder treatment. Arquivos de Neuro-Psiquiatria. https://doi.org/10.1590/s0004-282x2000000600008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.